CARDIOVASCULAR EFFECT OF CINNAMON CAPSULES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSIO
- Conditions
- Health Condition 1: I10- Essential (primary) hypertensionHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/05/052601
- Lead Sponsor
- Ajinkya Mukund Rahatgaonkar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion criteria
Age 30-60 years
Patients with type 2 diabetes mellitus based on ADA criteria.
Patient with Hypertension
Patients taking Oral hypoglycemic agents.
HbA1C: > 7
Patient with prior history of an allergy to cinnamon
Alcoholic liver disease (ALD), cirrhosis
On insulin therapy
Raised baseline serum creatinine levels ( >1.5 mg/dl in men or > 1.2 mg/dl in women)
Lactation, pregnancy
Patients with symptoms suggestive of peptic ulcer disease and those with a past history of peptic ulceration
Any malignancy
Patients with unrelated chronic illnesses and infections like Tuberculosis
Patients with cardiac, liver, or respiratory failure.
Patients with bleeding disorders and who are taking coumarin derivatives (e.g., warfarin)
Patients diagnosed with Acute coronary syndrome (CAD- Prior history of MI, angina)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method At the end of 12 weeks see the change in blood pressure, hs-CRP level, and Plasma homocysteine level.Timepoint: At the beginning of the study both groups will be analyzed for baseline Systolic and Diastolic Blood Pressure, CRPH, and plasma homocysteine level. Patients will be asked for follow-up after 12 weeks of treatment and repeat Systolic and Diastolic Blood Pressure, CRPH, Plasma homocysteine level will be measured
- Secondary Outcome Measures
Name Time Method â?¢AT the end of 12 weeks to see a change in HOMA-IR, glycemic control in the study group with the control group on standard therapy. <br/ ><br> <br/ ><br>Timepoint: At the beginning of the study, both groups will be analyzed for baseline HOMA-IR. Patients will be asked for follow-up after 12 weeks of treatment and repeat HOMA-IR level will be measured.